-- XRF Scientific(ASX:XRF)は、消耗品の好調と設備投資の勢いに支えられ、概ね予想通りの第3四半期決算を発表し、通期業績予想を据え置いたと、ユーロズ・ハートリーズ証券は水曜日のレポートで述べた。 同社は、3月期の税引前利益が前年同期の340万豪ドルから約11%増加し370万豪ドル、売上高は1390万豪ドルから14%増加し1580万豪ドルになったと報告した。 同社は、消耗品が第3四半期の業績を牽引し、売上高は480万豪ドルに達したと指摘した。これは、アジアにおける旺盛な需要、3月の過去最高の販売量、そしてほぼ即時納品が見込まれる100万豪ドルの受注残高が第4四半期に持ち越される見込みであることによるものだ。 同社は、設備投資収益が前年同期比20%増の540万豪ドルに達したことを強調した。これは、Orbis社の破砕機の好調な稼働が250万豪ドルの貢献を牽引し、金セクターの需要が次の四半期も引き続き好調を維持すると見込んでいる。 また、貴金属売上高は前年同期比14%増の560万豪ドルに達したと発表した。これは、プラチナ価格の下落に伴う期末需要の高まりと、価格軟化による新製品販売の促進が要因となっている。 同社は、生産量の増加、国際需要の堅調さ、堅調な設備投資計画、そして将来的な収益増につながる買収の可能性に支えられた持続的な成長見通しを挙げ、同社株に対して引き続き強気の見方を示した。 Euroz Hartleysは、XRF Scientific株に対する買い推奨と目標株価2.21豪ドルを維持した。
Related Articles
Research Alert: CFRA Keeps Buy Opinion On Shares Of The Hartford Insurance Group, Inc.
CFRA, an independent research provider, has providedwith the following research alert. Analysts at CFRA have summarized their opinion as follows:We trim our 12-month target price by $8 to $155, valuing HIG shares at 11.3x our 2026 operating EPS estimate of $13.75 (cut by $0.45) and at 10.6x our 2027 EPS estimate of $14.65 (cut by $0.30), vs. the shares' one-year average forward multiple of 10.3x and peer average of 13x. Q1 EPS of $3.09 vs. $2.20 a year ago missed our $3.60 estimate and $3.39 consensus view. Operating revenue growth of 6.2% was in line with our 6%-10% forecast, amid 5.3% earned premium growth, 13% higher net investment income, and 7.9% fee revenue growth. Q1 written premium growth of 4% and full-year 2025 growth of 7% bode well for 2026 revenue trends as premiums are earned. Underwriting results improved significantly, with Personal Lines combined ratio improving to 87.7% from 106.1% and underlying combined ratio to 85.0% from 89.7%. Business Insurance combined ratio was stable at 94.8%. Weighing the Q1 EPS miss with HIG's decent top-line growth and discounted valuation to peers, we view the shares as undervalued.
Research Alert: CFRA Keeps Strong Buy Opinion On Shares Of Baker Hughes
CFRA, an independent research provider, has providedwith the following research alert. Analysts at CFRA have summarized their opinion as follows:We raise our 12-month target price by $14 to $82, reflecting a combination of our sum-of-the-parts (SOTP) and DCF models. For our SOTP model, we presume the oilfield services business (about 50% of BKR's franchise) to be valued at about 10x projected 2027 EBITDA (in line with major peers) and its industrial energy technology business (the other 50%) valued at 14x projected 2027 EBITDA (in line with the peer median). This blended approach, yielding a 12x multiple, implies a value of $73 per share. Meanwhile, our DCF model, using medium-term free cash flow growth of 5% per year, terminal growth of 2.5%, discounted at a WACC of 6.3%, yields intrinsic value of $91 per share. We cut our 2026 EPS estimate by $0.47 to $2.48, but we raise 2027's by $0.07 to $3.24. We acknowledge that the oilfield services business is likely to struggle in 2026 owing to the U.S.-Iran conflict, but the IET business appears quite robust and likely to be a source of both accelerating revenue growth and margins.
Research Alert: CFRA Maintains Hold Opinion In Shares Of Wab
CFRA, an independent research provider, has providedwith the following research alert. Analysts at CFRA have summarized their opinion as follows:We lift our 12-month target to $285 from $275 following WAB's Q1 earnings print, valuing shares at 24.2x our 2027 EPS outlook of $11.76 (revised from $11.46; 2026 EPS estimate up to $10.57 from $10.50), a slight premium to WAB's long-term historical multiple average given structural improvements in earnings quality. While we are cautious on signs of overcapacity in the freight market, an elevated order backlog (12-month sits at over $9 billion), internal initiatives to shore up margins, and potential synergies from M&A activity positions WAB to continue growing earnings at double-digit rates in 2026-2027, in our view. Despite tariff-related cost pressures, WAB has done a commendable job of defending margins via a mix of pricing, lean manufacturing, and pruning of lower-profit operations. Q1 results were mixed but overall positive, in our view. We maintain our Hold recommendation on shares.